Dr. Hemming is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
55 Lake Ave N
Worcester, MA 01655Phone+1 508-334-3550Fax+1 774-442-9130
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2014 - 2017
Massachusetts General HospitalResidency, Internal Medicine, 2012 - 2015
Harvard Medical SchoolClass of 2012
Harvard UniversityPhD, 2007
Certifications & Licensure
MA State Medical License 2015 - 2025
NH State Medical License 2024 - 2024- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- 120 citationsTargeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcomaGerard L. Brien, David Remillard, Junwei Shi, Matthew L. Hemming, Jonathon Chabon
Elife. 2018-11-15 - 10 citationsConcurrent inhibition of CDK2 adds to the anti-tumour activity of CDK4/6 inhibition in GIST.Inga-Marie Schaefer, Matthew L Hemming, Meijun Z Lundberg, Matthew P Serrata, Isabel Goldaracena
British Journal of Cancer. 2022-11-01 - 72 citationsAlternative Splicing of Human Insulin-Degrading Enzyme Yields a Novel Isoform with a Decreased Ability To Degrade Insulin and Amyloid β-Protein†Wesley Farris, Malcolm A. Leissring, Matthew L. Hemming, and Alice Y. Chang, Dennis J. Selkoe
Biochemistry. 2005-05-03
Journal Articles
- Translational Insights into Gastrointestinal Stromal Tumor and Current Clinical AdvancesM C Heinrich, S George, M L Hemming, Annals of Oncology
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
